Compare XPOF & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | TNYA |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 178.5M |
| IPO Year | 2021 | 2021 |
| Metric | XPOF | TNYA |
|---|---|---|
| Price | $7.21 | $0.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $8.13 | $5.33 |
| AVG Volume (30 Days) | 406.2K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.24 | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.83 | $0.36 |
| 52 Week High | $11.14 | $2.35 |
| Indicator | XPOF | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 56.66 |
| Support Level | $6.81 | $0.64 |
| Resistance Level | $8.32 | $0.82 |
| Average True Range (ATR) | 0.42 | 0.05 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 74.87 | 87.27 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.